| Literature DB >> 34220964 |
Yasmeen Niazi1,2,3, Hauke Thomsen1,4, Bozena Smolkova5, Ludmila Vodickova6,7,8, Sona Vodenkova6, Michal Kroupa6,8, Veronika Vymetalkova6,7,8, Alena Kazimirova9, Magdalena Barancokova9, Katarina Volkovova9, Marta Staruchova9, Per Hoffmann10,11, Markus M Nöthen10, Maria Dusinska12, Ludovit Musak13, Pavel Vodicka6,7,8, Kari Hemminki1,8,14, Asta Försti1,2,3.
Abstract
DNA damage and unrepaired or insufficiently repaired DNA double-strand breaks as well as telomere shortening contribute to the formation of structural chromosomal aberrations (CAs). Non-specific CAs have been used in the monitoring of individuals exposed to potential carcinogenic chemicals and radiation. The frequency of CAs in peripheral blood lymphocytes (PBLs) has been associated with cancer risk and the association has also been found in incident cancer patients. CAs include chromosome-type aberrations (CSAs) and chromatid-type aberrations (CTAs) and their sum CAtot. In the present study, we used data from our published genome-wide association studies (GWASs) and extracted the results for 153 DNA repair genes for 607 persons who had occupational exposure to diverse harmful substances/radiation and/or personal exposure to tobacco smoking. The analyses were conducted using linear and logistic regression models to study the association of DNA repair gene polymorphisms with CAs. Considering an arbitrary cutoff level of 5 × 10-3, 14 loci passed the threshold, and included 7 repair pathways for CTA, 4 for CSA, and 3 for CAtot; 10 SNPs were eQTLs influencing the expression of the target repair gene. For the base excision repair pathway, the implicated genes PARP1 and PARP2 encode poly(ADP-ribosyl) transferases with multiple regulatory functions. PARP1 and PARP2 have an important role in maintaining genome stability through diverse mechanisms. Other candidate genes with known roles for CSAs included GTF2H (general transcription factor IIH subunits 4 and 5), Fanconi anemia pathway genes, and PMS2, a mismatch repair gene. The present results suggest pathways with mechanistic rationale for the formation of CAs and emphasize the need to further develop techniques for measuring individual sensitivity to genotoxic exposure.Entities:
Keywords: DNA repair; association study; chromosomal aberrations; exposure; polymorphism
Year: 2021 PMID: 34220964 PMCID: PMC8242355 DOI: 10.3389/fgene.2021.691947
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Descriptive attributes of the study cohort and exposure-based distribution.
| Age (years) | Median | 43 | 0.56 |
| Range | 19–80 | ||
| Gender (%) | Females | 40.5 | 0.05 |
| Males | 59.5 | ||
| Smoking status (%) | Smokers | 66.1 | 5.55E-05 |
| Non-smokers | 33.9 | ||
| Occupational exposure (n) | Small organic compounds | 316 | 2.42E-05 |
| Heavy metals | 6 | ||
| Radiation (pilots) | 6 | ||
| Asbestos | 19 | ||
| Stone wool | 28 | ||
| Glass fibers | 18 | ||
| Others | 214 | ||
| No. of individuals with | High CAtot freq | 342 | |
| Low CAtot freq | 265 | ||
| High CTA freq | 345 | ||
| Low CTA freq | 262 | ||
| High CSA freq | 321 | ||
| Low CSA freq | 286 | ||
Total 153 studied genes grouped based on DNA repair type (genes where the SNPs were associated with CAs are in bold letters).
SNP associations with P-value ≤ 5 × 10–3 from logistic and linear regression analyses of three CA types (CAtot, CTA, and CSA).
| Nucleotide excision repair (NER) | 1.7 kb 5′ of GTF2H4 | |||||||||
| Base excision repair (BER) PARP enzymes | rs1341334 | 1 | 226605024 | G | 1.56 | 1.21–2.00 | 5.16E-04 | 9.2 kb 5′ of PARP1/eQTL | ||
| Direct reversal of DNA damage | rs12247555 | 10 | 131370520 | C | 0.09 | 0.03–0.15 | 2.78E-03 | Intronic/eQTL | ||
| Base excision repair (BER) | rs10009807 | 4 | 178229925 | A | 0.69 | 0.54–0.89 | 4.62E-03 | 1.1 kb 5′ of NEIL3/histone marks | ||
| DNA polymerases (catalytic subunits) | rs7742724 | 6 | 111839019 | A | 1.63 | 1.23–2.16 | 6.42E-04 | eQTL | ||
| Fanconi anemia | rs17542001 | 17 | 59915590 | C | 0.64 | 0.48–0.85 | 1.86E-03 | Intronic/eQTL | ||
| Fanconi anemia | rs13292454 | 9 | 97995075 | A | 0.16 | 0.05–0.28 | 3.93E-03 | Intronic | ||
| Conserved DNA damage response genes | rs3094090 | 6 | 30669956 | C | 0.19 | 0.07–0.32 | 2.33E-03 | Intronic | ||
| DNA polymerases (catalytic subunits) | eQTL | |||||||||
| Non-homologous end-joining (NHEJ) | rs301286 | 5 | 82602955 | C | −0.14 | (−0.22)–(−0.05) | 1.42E-03 | Intronic/histone marks | ||
| Conserved DNA damage response genes | rs28702649 | 15 | 43648629 | T | 0.12 | 0.05–0.19 | 1.31E-03 | eQTL | ||
| Nucleotide excision repair (NER) | eQTL | |||||||||
| Base excision repair (BER) PARP enzymes | rs2318861 | 14 | 20758949 | G | 0.54 | 0.38–0.78 | 9.85E-04 | eQTL | ||
| Fanconi anemia | rs61429272 | 3 | 10037320 | C | 0.15 | 0.05–0.24 | 4.13E-03 | eQTL | ||
| Mismatch excision repair (MMR) | rs12702464 | 7 | 6041506 | C | −0.13 | (−0.21)–(−0.04) | 4.64E-03 | Intronic/eQTL | ||
Regulome DB 2.0/GTex in silico analysis of associated variants.
| 6 | rs3130780 | − | Blood + 102 | BCL6, MEF2A | − | − | − | ZNF792, MIXL1 | |
| 1 | rs1341334 | Blood (K562) + 9 other tissues | Enhancer in blood | BCL6, NANOG | Cultured fibroblasts | −0.31 | 9.00E-23 | ZFX,ZNF770 | |
| 10 | rs12247555 | − | Blood + 16 | − | Whole blood | −0.29 | 1.40E-33 | − | |
| 4 | rs10009807 | Blood, B cells, T cells | Enhancer in blood + 30 | − | − | − | − | POLR2A | |
| 17 | rs17542001 | − | Blood + 62 | − | Nerve–tibial | −0.41 | 7.30E-15 | − | |
| 9 | rs13292454 | Blood + 3 others | Blood + 48 | FOXJ3 | − | − | − | − | |
| 6 | rs3094090 | Tibial nerve | Blood + 123 | IRF3 | Whole blood | 0.13 | 6.40E-06 | ZNF664 | |
| 6 | rs7742724 | Mammary glands | Blood + 23 | − | Brain–Cerebellum | 0.28 | 1.40E-06 | SMARCA4 # | |
| 5 | rs301286 | Blood + 6 others | Active TSS in blood + 6 | − | − | − | − | STAT5A#, STAT3#, TBP# + 10 | |
| 15 | rs28702649 | Placenta, H9, OCI-LY7 | Blood + 109 | SOX1 | Cultured fibroblasts | −0.13 | 4.10E-08 | CTCF#, RAD21, ZBTB33# | |
| 6 | rs1744178 | H7-hESC, Lower leg | Blood + 118 | − | *Whole blood | * | 2.8783E-17 | − | |
| 14 | rs2318861 | − | Blood + 124 | − | *Whole blood | * | 6.61974E-07 | ZBTB40 | |
| 3 | rs61429272 | Naïve B cell + 9 other tissues | Blood + 99 | − | Whole blood | −0.17 | 2.70E-09 | − | |
| 7 | rs12702464 | − | Blood + 124 | − | Artery–aorta | −0.44 | 4.50E-12 | − | |